Platform Technology

We are developing new technologies to secure leading technologies in the areas of anti-cancer drugs and anti-cancer adjuvant drugs. We are preparing to construct oncology specialty systems based on our already-secured high-level technology.

With the aim of becoming a DDS specialist research center, we have set up strategies to continue to develop DDS technology and products with focus on technological competitiveness. We will thus continue our efforts to complement and bolster our existing DDS pipelines, and vow to commercialize our proprietary technology.
In the medical-devices area, for our R&D, we are positively using our accumulated experience and manufacturing technology relative to our accumulated diverse biodegradable polymer materials. To expand our portfolio of medical-device products, we are concentrating all our efforts on securing platform technologies.
We vow to use our accumulated platform technologies and grow as an innovative pharmaceutical company.

DDS Platform Technology

PM Technology

(Polymeric Micelle)

We used our Biomedicine Research Center’s proprietary solubilization technology, polymeric micelle, and developed the world’s first biodegradable polymer nanoparticles to be applied to the human body. We thus earned approval thereof. This platform technology can be applied not only to anti-cancer drugs but also to many other medications.

PNP Technology

(Polymeric Nano-Particle)

The PNP technology is a polymeric nanoparticle technology developed for the development of drug-resistant anti-cancer drugs, for minimizing the side effects of anti-cancer drugs, and for maximizing the cancer treatment effects. As such, the use of the PNP technology can drastically improve cancer treatment. Also, the use of nano-sized polymer particles can adjust the blood half-life of diverse drugs as well as the tissue distribution characteristics, thus maximizing the treatment effects.

siRNA Delivery Technology

To secure exclusive, leading technologies in the anti-cancer drug area, we are developing a platform technology for delivering siRNA to the whole body. We are concentrating on R&D to use this technology and to develop the siRNA drug in a bid to dominate the global markets.

PMP Technology

(Polymeric Microparticle)

The PMP technology can continue to release medications for a long time. The use of this technology can drastically reduce the amount of organic solvent waste produced while manufacturing drugs, and give easy access to protein or peptide drugs, which have difficulty maintaining their stability in organic solvents.

LAMP Technology

(Long Acting Microparticle)

This innovative technology is designed to use certain-pattern hydrogel templates with micro-sized holes and manufactured particles with a uniform distribution. The use of this technology can continue medication release for several weeks to several months. Thus, a one-time injection can produce long-time treatment effects.

PMS Technology

(Polymeric Microsphere)

The PMS technology can continue to release medications, and it can use PLACOONa/PLGA polymers and manufacture global particles. Generally, spray dryers used by pharmaceutical companies are used, thus making it simple to manufacture.

PoligoGel Technology

Compounds of temperature-susceptible polymers and drugs remain sol at low temperatures, and if this sol is injected into the body, it results in in-situ gelation due to the body temperature.
This technology also allows such created gel to serve as a depot to slowly release the medication. This technology is designed to maintain the stability of protein drugs and to continuously release medications.

FDT Technology

(Fast disintegrating tablet)

This technology designs a tablet to be disintegrated in the mouth within 30 seconds with saliva alone, without water, thus drastically boosting the convenience of patients taking drugs. As such, this technology can boost drug compliance for elderly people, children, patients with difficulty swallowing, travelers, mental patients, and patients with difficulty taking food and water.

CSDS Technology

(Colon specific delivery system)

The CSDS technology is designed to prevent medication from being released in or absorbed by the stomach and small intestine, allowing it instead to be released in or absorbed by only the large intestine. Unlike the general CSDS technology, ours designs the medication to be degraded only by large-intestine bacteria, thus allowing the medication to be released only in the large intestine, and consequently reducing the side effects and maximizing the medicinal effects.

BA Enhancing Technology


This technology can increase the solubility and absorption of orally taken, poorly-water-soluble drugs, thus drastically improving the use of drugs. It enables only a small amount of medication to produce sufficient treatment effects; thus, with high-priced drugs, the technology can drastically lower the costs and can minimize side effects of the drug.

SR Technology

(Sustained Release)

The oral SR technology controls the release of drugs and maintains the drug’s concentration in the blood after being taken at a certain level. The technology changes the drug intake frequency from over three a day to once or twice, thus improving the patient convenience of taking the drug. It can produce the medicinal effects with the same dose as the existing drug, and can minimize the side effects.

Medical-Device Platform Technology

HMW-ROP Technology

(High Molecular Weight – Ring opening polymerization)

The technology synthesizes the medical aliphatic polyester that can be degraded and absorbed in the body after a certain time following surgery. According to their strengths and degrading time, the technology formulates lactone monomers into diverse preparations and synthesizes them into polymers with low-dispersive molecular weight. Through the precise applied processing of synthesized polymers, they can be manufactured into absorbable surgical devices, such as high-strength surgical sutures, surgical meshes, absorbable stents, etc.

ORC Technology

(Oxidized Regenerated Cellulose)

The technology transforms cellulose – through diverse acid reactions – into the biodegradable oxidized regenerated cellulose (ORC), which can be used in the body. Together with the technology for controlling the meticulous structure of cellulose matrix and the oxidation limit, the technology can develop hemostatics with diverse efficacies and adhesion barriers.